Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Danegaptide (GAP-134), has been identified as a potent and selective second generation gap junction modifier with oral bioavailability.a small modified dipeptide.
Pack Size | Availability | Price/USD | Quantity |
---|---|---|---|
100 mg | 5 days | Inquiry | |
500 mg | 5 days | Inquiry |
Description | Danegaptide (GAP-134), has been identified as a potent and selective second generation gap junction modifier with oral bioavailability.a small modified dipeptide. |
In vitro | Danegaptide (GAP-134) is a pharmalogical agent with a favorable clinical safety profile and potential antiarrhythmic efficacy, as already confirmed in phase I clinical trials.Gap junction uncoupling can alter conduction pathways and promote cardiac re-entry mechanisms that potentiate many supraventricular arrhythmias, such as atrial fibrillation (AF) and atrial flutter (AFL).?Gap junction modifier Danegaptide (GAP-134), showed consistent efficacy on measures of conduction and AF/AFL inducibility in the canine sterile pericarditis model. |
Synonyms | ZP 1609, GAP-134 |
Molecular Weight | 291.3 |
Formula | C14H17N3O4 |
CAS No. | 943134-39-2 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
You can also refer to dose conversion for different animals. More
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
Danegaptide 943134-39-2 Others ZP 1609 GAP134 GAP 134 ZP1609 GAP-134 ZP-1609 inhibitor inhibit